Based on these observations, and on the lack of specific criteria for the evaluation of HER2 amplification in thyroid tumors, we analyzed the distribution of HER2+ cells in these cases to determine if they met the criteria for the presence of genetic heterogeneity (>5% and <50%) according to Vance [17]. The gene discussed is ERBB2; the disease is thyroid tumor.